Last reviewed · How we verify
NCT04295304: NR
NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases
NA trial testing Retinal surgery with implantation of epi-retinal device in Retinitis Pigmentosa in 9 participants. Terminated before completion.
9 March 2023
Quick facts
| Lead sponsor | Nano Retina |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 17 January 2020 |
| Primary completion | 9 March 2023 |
| Estimated completion | 12 March 2023 |
| Sites | 6 locations across Belgium, Italy, Israel |
Drugs / interventions tested
- Retinal surgery with implantation of epi-retinal device
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
- Retinal Degeneration — all drugs for Retinal Degeneration →
Sponsor
Nano Retina
Who can join
Adults 18 to 80, any sex, with Retinitis Pigmentosa or Retinal Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study objective is to demonstrate safety of the NR 600 System, and to evaluate the performance of the device in restoring visual activity of daily living in subjects with retinal degenerative diseases and severe visual impairment
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
An update on visual prosthesis.
Ramirez KA, Drew-Bear LE, Vega-Garces M, Betancourt-Belandria H, et al · · 2023 · cited 23× · PMID 37996905 · DOI 10.1186/s40942-023-00498-1 -
Tackling visual impairment: emerging avenues in ophthalmology.
Lin F, Su Y, Zhao C, Akter F, et al · · 2025 · cited 4× · PMID 40357281 · DOI 10.3389/fmed.2025.1567159
Verify or expand the search:
- PubMed search for NCT04295304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04295304 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nano Retina
- Last refreshed: 15 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04295304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing